Thinking twice before abandoning first-line chemotherapy in ovarian cancer: Report of two cases and literature review. Passing from tri-weekly to weekly regimens

  • Claudia Marchetti
  • , Filippo Bellati
  • , Angela Musella
  • , Chiara Napoletano
  • , Giorgia Perniola
  • , Violante Di Donato
  • , Sandro Pignata
  • , Marianna Nuti
  • , Pierluigi Benedetti Panici

Risultato della ricerca: Contributo in rivistaArticolo

Abstract

We present two cases of advanced ovarian cancer treated with neoadjuvant chemotherapy with standard tri-weekly carboplatin and paclitaxel. Therapy was converted to weekly regimens because of disease progression, resulting in disease response. Weekly regimens could overcome drug resistance and this strategy should be attempted before abandoning first-line chemotherapy in favor of palliation. © Japan Society of Clinical Oncology 2012.
Lingua originaleInglese
pagine (da-a)385-389
Numero di pagine5
RivistaInternational Journal of Clinical Oncology
Volume17
DOI
Stato di pubblicazionePubblicato - 2012

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

  1. SDG 3 - Salute e benessere
    SDG 3 Salute e benessere

Keywords

  • Carboplatin
  • Ovarian cancer
  • Weekly paclitaxel

Fingerprint

Entra nei temi di ricerca di 'Thinking twice before abandoning first-line chemotherapy in ovarian cancer: Report of two cases and literature review. Passing from tri-weekly to weekly regimens'. Insieme formano una fingerprint unica.

Cita questo